Es gab 50 kürzliche Insider-Transaktionen für Rubius Therapeutics, Inc. (RUBY), darunter 32 Käufe und 15 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $7.01M und die gesamten Insider-Verkäufe auf $2.46M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Appelhans Dannielle, Cagnoni Pablo J, Turka Laurence A.. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — RUBY
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2023-02-24 |
Appelhans Dannielle |
CEO and President |
Informierter Verkauf |
10,385 |
$0.13 |
$1.32K |
- |
| 2023-02-01 |
Cagnoni Pablo J |
Director |
Informierter Verkauf |
8,448 |
$0.25 |
$2.11K |
66,082 |
| 2023-02-01 |
Appelhans Dannielle |
CEO and President |
Informierter Verkauf |
3,878 |
$0.25 |
$969.50 |
10,385 |
| 2023-01-31 |
Cagnoni Pablo J |
Director |
Informierter Verkauf |
7,240 |
$0.24 |
$1.74K |
74,530 |
| 2023-01-31 |
Turka Laurence A. |
Chief Scientific Officer |
Informierter Verkauf |
2,593 |
$0.24 |
$622.32 |
18,391 |
| 2023-01-31 |
Appelhans Dannielle |
CEO and President |
Optionsausübung |
7,500 |
- |
- |
14,263 |
| 2023-01-29 |
Cagnoni Pablo J |
Director |
Optionsausübung (Verkauf) |
21,250 |
- |
- |
42,500 |
| 2023-01-29 |
Turka Laurence A. |
Chief Scientific Officer |
Optionsausübung |
7,438 |
- |
- |
12,359 |
| 2022-08-09 |
Appelhans Dannielle |
Chief Operating Officer |
Informierter Verkauf |
5,737 |
$0.80 |
$4.59K |
6,763 |
| 2022-07-29 |
Schaffert Susanne |
Director |
RSU-Zuteilung |
50,000 |
- |
- |
50,000 |
| 2022-07-12 |
Schaffert Susanne |
Director |
Unbekannt |
- |
- |
- |
- |
| 2022-05-12 |
Afeyan Noubar |
10 Percent Owner |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Epstein David R |
Director |
RSU-Zuteilung |
499,762 |
- |
- |
499,762 |
| 2022-05-12 |
Rosenblatt Michael |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Cuss Francis M |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Sohn Catherine A. |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Holles Natalie C. |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Symonds Jonathan |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Prener Anne |
Director |
RSU-Zuteilung |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-04-21 |
Epstein David R |
Director |
Informierter Kauf |
30,000 |
$1.44 |
$43.33K |
4,720,012 |
| 2022-02-01 |
Cagnoni Pablo J |
CEO and President |
Informierter Verkauf |
6,730 |
$6.57 |
$44.24K |
35,520 |
| 2022-02-01 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Informierter Verkauf |
2,732 |
$6.57 |
$17.96K |
5,343 |
| 2022-02-01 |
Turka Laurence A. |
Chief Scientific Officer |
Informierter Verkauf |
2,517 |
$6.57 |
$16.54K |
4,921 |
| 2022-01-31 |
Cagnoni Pablo J |
CEO and President |
RSU-Zuteilung |
100,000 |
- |
- |
100,000 |
| 2022-01-31 |
Carmona Jose |
Chief Financial Officer |
RSU-Zuteilung |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
RSU-Zuteilung |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Turka Laurence A. |
Chief Scientific Officer |
RSU-Zuteilung |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Appelhans Dannielle |
Chief Operating Officer |
RSU-Zuteilung |
30,000 |
- |
- |
30,000 |
| 2022-01-29 |
Cagnoni Pablo J |
CEO and President |
Optionsausübung |
21,250 |
- |
- |
42,250 |
| 2022-01-29 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Optionsausübung |
8,075 |
- |
- |
8,075 |
| 2022-01-29 |
Turka Laurence A. |
Chief Scientific Officer |
Optionsausübung |
7,438 |
- |
- |
7,438 |
| 2021-12-31 |
Cagnoni Pablo J |
CEO and President |
Unbekannt |
- |
- |
- |
- |
| 2021-08-31 |
Appelhans Dannielle |
Chief Operating Officer |
RSU-Zuteilung |
50,000 |
- |
- |
50,000 |
| 2021-08-09 |
Appelhans Dannielle |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2021-05-12 |
Afeyan Noubar |
10 Percent Owner |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Epstein David R |
Director |
RSU-Zuteilung |
27,919 |
$23.25 |
$649.12K |
27,919 |
| 2021-05-12 |
Rosenblatt Michael |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Cuss Francis M |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Sohn Catherine A. |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Holles Natalie C. |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Symonds Jonathan |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Prener Anne |
Director |
RSU-Zuteilung |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-03-19 |
Flagship Ventures Fund Iv General Partner Llc |
10 Percent Owner |
Informierter Kauf |
70,000 |
$29.00 |
$2.03M |
2,633,703 |
| 2021-03-15 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Informierter Verkauf |
25,000 |
$20.24 |
$505.97K |
- |
| 2021-02-11 |
Epstein David R |
Director |
Informierter Verkauf |
26,704 |
$14.93 |
$398.56K |
4,690,012 |
| 2021-02-10 |
Epstein David R |
Director |
Informierter Verkauf |
7,404 |
$14.79 |
$109.53K |
4,716,716 |
| 2021-02-09 |
Epstein David R |
Director |
Informierter Verkauf |
2,100 |
$14.83 |
$31.15K |
4,724,120 |
| 2021-02-08 |
Epstein David R |
Director |
Informierter Verkauf |
89,233 |
$14.88 |
$1.33M |
4,726,220 |
| 2021-01-29 |
Cagnoni Pablo J |
CEO and President |
RSU-Zuteilung |
85,000 |
- |
- |
85,000 |
| 2021-01-29 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
RSU-Zuteilung |
32,300 |
- |
- |
32,300 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall